FY2025 EPS Estimate for Lexeo Therapeutics Raised by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for Lexeo Therapeutics in a report released on Wednesday, November 5th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.87) for the year, up from their prior estimate of ($2.30). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q4 2025 earnings at ($0.28) EPS, FY2026 earnings at ($1.14) EPS and FY2027 earnings at ($1.30) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15.

Other analysts have also recently issued research reports about the stock. Leerink Partners boosted their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday, November 5th. Oppenheimer assumed coverage on Lexeo Therapeutics in a report on Thursday, July 31st. They issued an “outperform” rating and a $20.00 target price on the stock. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.57.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $9.12 on Monday. The stock has a fifty day moving average of $7.40 and a 200-day moving average of $5.21. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $11.72. The stock has a market capitalization of $492.48 million, a price-to-earnings ratio of -3.38 and a beta of 1.75.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new stake in Lexeo Therapeutics during the second quarter worth $60,000. Ethic Inc. purchased a new position in shares of Lexeo Therapeutics in the second quarter worth $44,000. Affinity Asset Advisors LLC acquired a new stake in Lexeo Therapeutics during the 1st quarter worth about $5,139,000. Palumbo Wealth Management LLC acquired a new stake in shares of Lexeo Therapeutics during the second quarter worth about $226,000. Finally, Privium Fund Management B.V. boosted its holdings in shares of Lexeo Therapeutics by 11.3% in the 2nd quarter. Privium Fund Management B.V. now owns 178,356 shares of the company’s stock valued at $753,000 after acquiring an additional 18,158 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 13,133 shares of the firm’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the sale, the chief executive officer owned 242,118 shares of the company’s stock, valued at $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the transaction, the insider owned 73,261 shares in the company, valued at $654,953.34. This represents a 4.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 29,091 shares of company stock valued at $232,007. 5.30% of the stock is currently owned by insiders.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.